December 20, 2018

Mustang Bio to process rare cancer drug in Worcester

Photo | Courtesy
Mustang Bio's building in Worcester.
New York biotech Mustang Bio is already putting its new Worcester facility to use, as the lab will help the company process a new drug to treat a rare and incurable cancer.

The company announced Thursday an Orphan Drug Designation from the U.S. Food and Drug Administration for MB-102, which the company hopes can treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), a deadly blood cancer with a medial survival less than 18 months.

Mustang will process MB-102 in its newly built CAR-T cell therapy manufacturing facility at UMass Medicine Science Park.

In a statement, Martina Sersch, chief medical officer at the company, said the drug has the potential to address an area of high unmet medical need.

"This significant milestone for Mustang will provide additional market exclusivity and financial benefits to advance MB-102, which we believe is an important new treatment for patients with BPDCN," Sersch said.

The drug is being studied at a California research center, hospital and medical school in a first-in-human, phase 1 clinical trial to evaluate the safety and anti-tumor activity of the drug in patients with relapsed or refractory acute myeloid leukemia and BPDCN.

The company last month said early results from the study have been positive.


Type your comment here:

Today's Poll Will there be alcohol at your company holiday party? <>
Most Popular on Facebook
Copyright 2017 New England Business Media